← All indications
Hyperaldosteronism
A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
Subtype terms (1)
More specific conditions that are subtypes of Hyperaldosteronism in the MeSH hierarchy.
Drugs by status
Approved for this indication (3)
Phase 4 trials (9)
Phase 3 trials (2)
Phase 2 trials (6)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (4)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (11)
- Daiichi Sankyo
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Padova
- Chongqing Medical University
- University of Cambridge
- Vanderbilt University
- The Royal Wolverhampton NHS Trust
- Paris Descartes University
- University of Alabama, Birmingham
- the Chongqing Primary Aldosteronism Study (CONPASS) Group